Document Type : Original Article
Authors
- Pouyan Ebrahimi 1
- AmirHossein Nasiri-Valikboni 1
- Mahmoud Sadeghi Haddad Zavareh 2
- Hoda Shirafkan 3
- Seyed Hassan Abedi 4
1 Student Committee Research, Babol University of Medical Science, Babol, Iran
2 Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
3 Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
4 Department of Internal Medicine, School of Medicine, Babol University of Medical Sciences, Babol, Iran
Abstract
Background:
Coronavirus 2019 (COVID-19) disease caused a recent pandemic that killed thousands of people by causing mild and severe systemic organ involvement. Researchers are still trying to find the proper diagnosis tool for the disease. In addition, we investigated the effect of aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) enzymes on long-term outcomes.
Methods:
The variables in this retrospective cohort study were collected from the records of patients with Covid-19 referred to Rouhani Hospital in Mazandaran, northern Iran. Patients were followed up to the cut-off points for mortality.
Results:
Among 320 eligible patients, AST levels, unlike ALT and ALP, were significantly associated with mortality (p<0.001) and disease severity (p=0.016). The level of AST, unlike the level of other tests examined at the time of referral, has a significant effect on mortality at admission time (p < 0.001, 95% CI= 2.433 to 20.463, MD = 7.056) and time of admission to the intensive care unit (ICU) (P = 0.012, 95% CI= 1.291 to 7.907, MD = 3.195). None of the tests (AST, ALT and ALP) could predict long-term mortality in patients.
Conclusions:
AST levels, unlike ALP and ALT levels, have shown an excellent ability to predict mortality and severity at admission, but neither of AST, ALT and ALP predicted long-term adverse outcomes.
Keywords
Main Subjects
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. doi: 10.1056/ NEJMoa2001017.
- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-44. doi: 10.1038/s41564-020-0695-z.
- Lovato A, de Filippis C, Marioni G. Upper airway symptoms in coronavirus disease 2019 (COVID-19). Am J Otolaryngol. 2020;41(3):102474. doi: 10.1016/j.amjoto.2020.102474.
- Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J Zhejiang Univ Sci B. 2020;21(5):343-60. doi: 10.1631/jzus.B2000083.
- Nicola M, O’Neill N, Sohrabi C, Khan M, Agha M, Agha R. Evidence based management guideline for the COVID-19 pandemic - review article. Int J Surg. 2020;77:206-16. doi: 10.1016/j.ijsu.2020.04.001.
- Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4. doi: 10.1186/ s40779-020-0233-6.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. doi: 10.1016/s0140-6736(20)30211-7.
- Rodriguez-Guerra M, Jadhav P, Vittorio TJ. Current treatment in COVID-19 disease: a rapid review. Drugs Context. 2021;10:2020-10-3. doi: 10.7573/dic.2020-10-3.
- Hebbani AV, Pulakuntla S, Pannuru P, Aramgam S, Badri KR, Reddy VD. COVID-19: comprehensive review on mutations and current vaccines. Arch Microbiol. 2021;204(1):8. doi: 10.1007/s00203-021-02606-x.
- Eugster AK, Albert PJ, Kalter SS. Multiple enzyme determinations in sera and livers of tumor bearing hamsters. Proc Soc Exp Biol Med. 1966;123(2):327-31. doi: 10.3181/00379727-123-31479.
- Yang X, Schnackenberg LK, Shi Q, Salminen WF. Hepatic toxicity biomarkers. In: Gupta RC, ed. Biomarkers in Toxicology. Boston: Academic Press; 2014. p. 241-59. doi: 10.1016/b978-0-12-404630-6.00013-0.
- McPherson RA, Pincus MR. Henry’s Clinical Diagnosis and Management by Laboratory Methods E-Book. Elsevier Health Sciences; 2021.
- Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. 2020;40(6):1278-81. doi: 10.1111/ liv.14470.
- Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561-6. doi: 10.1016/j.cgh.2020.04.002.
- Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int. 2020;40(9):2095-103. doi: 10.1111/liv.14455.
- Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4):1363-70. doi: 10.1002/hep.22109.
- Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. Intensive Care Med. 2020;46(2):357-60. doi: 10.1007/s00134-020-05954-2.
- Kang SJ, Jung SI. Age-related morbidity and mortality among patients with COVID-19. Infect Chemother. 2020;52(2):154- 64. doi: 10.3947/ic.2020.52.2.154.
- Cen Y, Chen X, Shen Y, Zhang XH, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study. Clin Microbiol Infect. 2020;26(9):1242- 7. doi: 10.1016/j.cmi.2020.05.041.
- Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal liver tests in COVID-19: a retrospective observational cohort study of 1,827 patients in a major US hospital network. Hepatology. 2020;72(4):1169-76. doi: 10.1002/hep.31487.
- Ding ZY, Li GX, Chen L, Shu C, Song J, Wang W, et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. 2021;74(6):1295-302. doi: 10.1016/j.jhep.2020.12.012.
- Hu L, Chen S, Fu Y, Gao Z, Long H, Ren HW, et al. Risk factors associated with clinical outcomes in 323 coronavirus disease 2019 (COVID-19) hospitalized patients in Wuhan, China. Clin Infect Dis. 2020;71(16):2089-98. doi: 10.1093/ cid/ciaa539.
- Clark R, Waters B, Stanfill AG. Elevated liver function tests in COVID-19: causes, clinical evidence, and potential treatments. Nurse Pract. 2021;46(1):21-6. doi: 10.1097/01. NPR.0000722316.63824.f9.
- Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020;72(2):389-98. doi: 10.1002/hep.31301.
- Mertoglu C, Huyut MT, Arslan Y, Ceylan Y, Coban TA. How do routine laboratory tests change in coronavirus disease 2019? Scand J Clin Lab Invest. 2021;81(1):24-33. doi: 10.1080/00365513.2020.1855470.
- Pott-Junior H, Bittencourt NQP, Chacha SFG, Luporini RL, Cominetti MR, Anibal FF. Elevations in liver transaminases in COVID-19: (how) are they related? Front Med (Lausanne). 2021;8:705247. doi: 10.3389/fmed.2021.705247.
- Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado- Alanoca A, Alarcon-De-la-Vega G, Alvarado-Arnez LE, Balderrama-Saavedra MA, et al. Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) in Bolivia: an analysis of the first 107 confirmed cases. Infez Med. 2020;28(2):238-42.
- Lv Z, Lv S. Clinical characteristics and analysis of risk factors for disease progression of COVID-19: a retrospective cohort study. Int J Biol Sci. 2021;17(1):1-7. doi: 10.7150/ijbs.50654.
- Kim L, Garg S, O’Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)- associated hospitalization surveillance network (COVID-NET). Clin Infect Dis. 2021;72(9):e206-14. doi: 10.1093/cid/ ciaa1012.
)